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Abstract
TEA domain (TEAD) transcription factors bind to the co-activator YAP/TAZ, and regulate the 
transcriptional output of Hippo pathway, playing critical roles in organ size control and 
tumorigenesis. Protein S-palmitoylation attaches fatty acid (palmitate) to cysteine residues, and 
regulates protein trafficking, membrane localization and signaling activities. Using activity-based 
chemical probes, we discovered that human TEADs possess intrinsic palmitoylating enzyme-like 
activities, and undergo autopalmitoylation at evolutionarily conserved cysteine residues under 
physiological conditions. We determined the crystal structures of lipid-bound TEADs, and found 
that the lipid chain of palmitate inserts into a conserved deep hydrophobic pocket. Strikingly, 
palmitoylation is required for TEAD’s binding to YAP/TAZ, but dispensable for the binding to 
Vgll4 tumor suppressor. In addition, palmitoylation does not alter TEAD’s localization. Moreover, 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#termsReprints and 
permissions information is available online at http://www.nature.com/reprints/index.html.
*Correspondence: ; Email: xuelian.luo@utsouthwestern.edu (X.L.), ; Email: xwu@cbrc2.mgh.harvard.edu (X.W.)
5Co-first authors
Accession codes
Protein Data Bank (PDB): coordinates for the TEAD2-PLM complex have been deposited with accession code 5HGU.
Author contributions
X.W conceived the concepts, designed the experiments and supervised the studies. P.C. designed and performed the cell biology and 
biochemistry experiments with the help of M.D. X.H. performed protein purification, crystallization, and structure determination, and 
carried out mass spectrometry analysis of TEAD2 autopalmitoylation. B.Z. and G.J. synthesized the probes. B.Z. identified TEAD 
from mass spec studies and tested DHHC-family of PATs. J.Y, H.D, and D.P carried out Drosophila genetics experiments. X.L. 
contributed to experimental design and structure refinements of palmitate-bound TEAD2 and TEAD1-YAP complex. P.C., D.P, X.L 
and X.W. analyzed the data; P.C, D.P. X.L and X.W wrote the manuscript with input from all co-authors.
Competing financial interests
The authors declare no competing financial interests.
Any supplementary information, chemical compound information and source data are available in the online version of the paper.
HHS Public Access
Author manuscript
Nat Chem Biol. Author manuscript; available in PMC 2016 August 22.
Published in final edited form as:
Nat Chem Biol. 2016 April ; 12(4): 282–289. doi:10.1038/nchembio.2036.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
TEAD palmitoylation-deficient mutants impaired TAZ-mediated muscle differentiation in vitro, 
and Yorkie-mediated tissue overgrowth in Drosophila in vivo. Our study directly linked 
autopalmitoylation to the transcriptional regulation of Hippo pathway.
INSTRODUCTION
Hippo signaling plays key roles in organ size control and tumor suppression1,2. The signal 
transduction involves a core kinase cascade, including MST1/2 and Lats1/2 kinases, leading 
to YAP/TAZ phosphorylation, cytoplasmic retention and inhibition3. Physiological or 
pathological inactivation of these kinases leads to YAP/TAZ dephosphorylation and nuclear 
accumulation. Subsequently, nuclear YAP/TAZ binds to the TEA domain transcription 
factors (TEAD1–4 in mammals, and Scalloped in Drosophila) to mediate the target genes 
expression3,4. The TEAD–YAP complex regulates normal development of skin, muscle, 
lung and liver, and are also oncogenic factor amplified in many human cancers5,6. TEADs 
can also bind to Vgll4, which has been implicated as a tumor suppressor by competing with 
YAP/TAZ for TEADs binding7,8. Therefore, TEADs are essential in regulating the 
transcriptional output of Hippo pathway. Although targeting TEAD–YAP could be a 
promising therapeutic approach for diseases with deregulated Hippo pathway9, it remains 
challenging to directly inhibit transcription factors with small molecules. Therefore, 
understanding the regulation of TEADs might reveal new therapeutic opportunities for drug 
discovery.
Post-translational S-palmitoylation attaches a 16-carbon palmitate to the cysteine residue 
through a reversible thioester bond. A large number of palmitoylated proteins have been 
identified through proteomic studies10–14. Dynamic S-palmitoylation plays critical roles 
regulating the trafficking, membrane localization and functions of many proteins, including 
Src-family kinases, GTPases, and synaptic adhesion molecules15,16. Asp-His-His-Cys 
(DHHC) family proteins are evolutionarily conserved protein palmitoyl acyltransferases 
(PATs)10, mediating enzymatic S-palmitoylation17. In addition, some proteins could bind to 
palmitoyl-Coenzyme A (CoA) directly, and undergo PAT-independent autopalmitoylation18. 
However, autopalmitoylation is poorly characterized. Most of the reported examples of 
autopalmitoylation are observed under non-physiological, high concentration of palmitoyl-
CoA (>100 µM)19. To date, only a few proteins, including yeast transporter protein Bet3, are 
autopalmitoylated under physiological concentrations of palmitoyl-CoA (1–10 µM)18,20. 
Therefore, it is important to reveal additional autopalmitoylated proteins and to understand 
their regulations and functions.
Towards this end, we have developed activity-based chemical probes based on irreversible 
inhibitors of PATs, 2-bromopalmitate (2-BP) and cerulenin, which inhibit palmitoylating 
activities by alkylating the active site cysteines of the enzymes or autopalmitoylated 
proteins21. We have synthesized analogues of 2-BP and cerulenin with an alkyne tail, which 
serve as bioorthogonal chemical reporters for covalently labeling and profiling PATs and 
autopalmitoylated proteins22,23. Through proteomic and biochemical studies, we have 
identified that the TEAD transcription factors are palmitoylated at evolutionarily conserved 
cysteine residues. We found that TEADs undergo PAT-independent autopalmitoylation, 
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under physiological concentrations of palmitoyl-CoA. We determined the crystal structures 
of the lipid-bound TEADs, and revealed a new ligand-binding site in TEADs. Furthermore, 
autopalmitoylation plays critical roles in regulating TEAD–YAP association and their 
physiological functions in vitro and in vivo. Therefore, palmitoylation of TEADs plays 
important roles in regulating Hippo pathway transcriptional complexes.
RESULTS
TEAD transcription factors are palmitoylated
To detect protein palmitoylation, analogues of palmitate, such as 15-hexadecynoic acid (Fig. 
1a, 1), have been widely used as chemical reporters to metabolically label palmitoylated 
proteins (substrates)24,25. To explore PATs and autopalmitoylated proteins, we synthesized 
the activity-based chemical probes, 2-bromohexadec-15-ynoic acid (2) and cis-2,3-epoxy-4-
oxooctadec-17-ynamide (3), respectively22,23. We have performed labeling, enrichment and 
proteomic analysis of the probe-labeled proteins and found that 2 and 3 can covalently label 
>300 proteins, including several known PATs and acyltransferases22,23.
Among the hits from chemoproteomic studies, we identified the TEA domain (TEAD/TEF) 
transcription factors (TEAD1 and TEAD3), with multiple unique matching peptides in 
proteomic studies (Supplementary Results, Supplementary Fig. 1a). TEADs bind to the 
transcription co-activator YAP/TAZ, and regulate the transcriptional output of Hippo 
pathway4–6,26, which plays critical roles in organ size control, regeneration and 
tumorigenesis1. To validate that TEADs are palmitoylated, we transfected Myc-TEAD1 and 
TEAD4 constructs in HEK293A cells; and then labeled cells with 50 µM of 1 or 2, followed 
by Cu-catalyzed 1,3-dipolar cycloaddition (Click reaction) with biotin-azide, and detection 
with streptavidin blots. Myc-TEAD1 and TEAD4 are indeed labeled by both probes (Fig. 
1b), suggesting that TEADs are palmitoylated. To characterize whether endogenous TEAD 
proteins are palmitoylated, HEK293A and MCF10A cells were metabolically labeled with 1, 
followed by Click reaction with biotin-azide. The palmitoylated proteins were then enriched 
by streptavidin beads pull-down. We successfully detected all four endogenous human 
TEADs (TEAD1–4) in the pull-down samples by western blots (Fig. 1c), indicating that they 
were indeed palmitoylated in cells. TEAD2 and 4 were not among the hits in chemical 
proteomics studies, possibly due to their low abundance, and our stringent criteria for mass 
spectra analysis. Nevertheless, our detailed biochemical experiments confirmed that all 
TEADs should be palmitoylated in cells. Similarly, Drosophila Scalloped protein is 
palmitoylated (Supplementary Fig. 1b), suggesting that TEAD palmitoylation is 
evolutionarily conserved. In addition, TEAD1 can also be labeled by 3 (Supplementary Fig. 
1c). Furthermore, treatment of hydroxylamine dramatically reduced the palmitoylation levels 
in TEAD1, suggesting that TEADs are S-palmitoylated through a reversible thioester 
linkage (Fig. 1d). Taken together, our results have revealed that TEAD family transcription 
factors are S-palmitoylated.
TEADs are palmitoylated at conserved cysteine residues
To identify the sites of palmitoylation in TEAD, we aligned sequences of TEAD family of 
proteins across different species, including human, Xenopus, zebra fish, Drosophila, and C. 
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elegans. We found that three cysteine residues are evolutionarily conserved (Supplementary 
Fig. 2a). We speculated that these conserved cysteine residues might play roles in TEAD 
palmitoylation. We have mutated these residues to serine in human TEAD1 (C53S, C327S 
and C359S), and tested whether the mutation affects TEAD1 palmitoylation. C359S mutant 
showed the greatest loss of palmitoylation, and C327S and C53S also showed decreased 
palmitoylation (Fig. 2a). These results suggest that C359 plays a critical role in TEAD1 
palmitoylation, and might be a major site of modification. Furthermore, combination 
mutation of all three cysteine residues, C53/327/359S (3CS), completely ablated TEAD1 
palmitoylation (Fig. 2b), indicating that these residues are indeed involved for TEAD1 
palmitoylation.
TEADs undergo PATs-independent autopalmitoylation
Since TEADs could be labeled by Probe 2 and 3 (Fig. 1b, Supplementary Fig. 1c), we 
hypothesized that TEADs might possess palmitoylating enzyme-like activities and undergo 
autopalmitoylation. We previously have purified recombinant TEAD2 protein27, allowing us 
to readily carry out in vitro experiments using TEAD2. We incubated recombinant hTEAD2 
(full-length or YAP-binding domain (YBD): TEAD2217–447) with a clickable analogue of 
palmitoyl-CoA (15-hexadecynoic CoA) at neutral pH in vitro, followed by Click reaction 
with biotin-azide and streptavidin blot. Both TEAD2 full-length and the YBD are 
palmitoylated in vitro in the absence of PATs (Fig. 2c, Supplementary Fig. 2b). In addition, 
overexpression of each of the DHHC-family PATs did not significantly alter the 
palmitoylation levels of TEAD1 in cells (Supplementary Fig. 2c), confirming that TEAD 
palmitoylation is independent of PATs. We then carried out intact mass spectrometry 
analysis of the recombinant TEAD2-YBD. We have identified the peak corresponding to the 
unmodified TEAD2 (26497 Dalton). Interestingly, we have observed a small side peak 
(26736 Dalton) (Fig. 2d), consistent with a palmitate modification to the protein. These 
results suggest that a small fraction of the recombinant TEAD2-YBD is palmitoylated when 
expressed in bacteria. In addition, after incubating with palmitoyl-CoA in vitro, we observed 
that the abundance of the palmitoylated TEAD2 peak (26736 Dalton) increased significantly 
(Supplementary Fig. 3a), further confirming that TEAD2 can be autopalmitoylated. 
Moreover, autopalmitoylation of TEAD2 YBD was confirmed by acyl-biotin exchange 
(ABE) assay, which converts S-palmitoylation to stable biotinylation for detection (Fig. 2e). 
With 1 µM of palmitoyl-CoA at neutral pH, TEAD2 YBD was autopalmitoylated within 2 
min, and the palmitoylation levels reached saturation after 10 min (Supplementary Fig. 3b). 
To determine dose-dependency of palmitoyl-CoA, recombinant TEAD2 YBD was incubated 
with various concentrations of alkyne palmitoyl-CoA for 3 min, and the reaction rate was 
determined by quantifying the intensities of streptavidin blots (Supplementary Fig. 3c). We 
estimated that the apparent Km of palmitoyl-CoA in TEAD2 autopalmitoylation is around 
0.8 µM (Fig. 2f), which is comparable to the Km of DHHC-family PATs28. The 
physiological palmitoyl-CoA concentrations range from 100 nM to 10 µM in cells29. 
Therefore, our results suggested that TEAD palmitoylation indeed could happen under 
normal physiological conditions. To the best of our knowledge, TEADs are the first 
autopalmitoylated transcription factors, linking cellular palmitoyl-CoA levels directly to 
transcription factor regulation.
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Structural analysis of palmitoylation of TEADs
To reveal the structural basis of lipid modification of TEADs, we carried out X-ray 
crystallography studies of TEAD2 YBD (residue 217–447). We expressed and purified 
native human TEAD2 YBD from bacteria, and determined its structure to a resolution of 2.0 
Å (PDB code 5HGU) by molecular replacement with the selenomethionine-labeled TEAD2 
YBD (PDB code 3L15)27 as the search model (Supplementary Table 1). We observed clear 
extra electron density in a deep hydrophobic pocket adjacent to C380 (corresponding to 
C359 of TEAD1), indicating that TEAD2 binds to an unknown small molecule ligand. 
Consistent with our results of TEAD2 palmitoylation by the chemical biology methods and 
mass spectrometry (Fig. 2d), we found that the extra electron density indeed corresponds to 
a 16-carbon fatty acid (palmitate, PLM) (Fig. 3a). The lipid chain of palmitate inserts deeply 
into the pocket, with the free carboxyl group pointing to, but not covalently attached to, 
C380 of TEAD2. We reasoned that the palmitate might initially be covalently attached to 
C380, but the labile thioester bond might be cleaved during purification and crystallization 
under slightly basic conditions. Consistently, surface drawing of TEAD2 reveals that the 
carboxyl group of palmitate is solvent accessible through an opening adjacent to C380 (Fig. 
3b). This opening is also large enough to allow free palmitate to diffuse in and out of the 
pocket. Interestingly, a recent report of TEAD2 structure using a slightly different 
purification conditions resulted in higher yield of palmitoylated TEAD2, and the covalent 
bond can be observed in crystal structures30.
To explore whether covalent palmitoylation could be observed in other TEAD structures. We 
revisited the previously reported crystal structures of human TEAD1–YAP complex (PDB 
code 3KYS), mouse TEAD4-YAP (PDB code 3JUA), and human TEAD1-cyclic YAP (PDB 
code 4RE1)31–33. We have observed that similar lipid-like electron densities are present in 
all of the conserved deep pocket of these structures. In mTEAD4-YAP (3JUA), the electron 
density appeared to be covalently connected to C360 of TEAD4. However, the electron 
densities in 3JUA and 4RE1 are truncated, making it difficult to assign to PLM without prior 
knowledge of palmitoylation (Supplementary Fig.4a and 4b). The TEAD1-YAP complex 
(PDB code 3KYS), which was co-expressed in bacteria and purified as a complex, showed 
the highest quality of electron density in the hydrophobic pocket. We refined the structure, 
and found that the electron density indeed corresponds to a palmitate, covalently linked to 
C359 of TEAD1 (Fig. 3c). These results are consistent with our biochemical findings that 
TEAD1 C359 is palmitoylated. Interestingly, the surface opening observed in TEAD2 alone 
structure is blocked by the β1 segment of YAP peptide in the TEAD1–YAP complex (Fig. 
3d). Therefore, the thioester bond is solvent inaccessible in the complex, together with the 
mild purification and crystallization conditions, it might help to preserve the covalent 
linkage. As there are no PATs present in bacteria, these findings also confirmed our results 
that TEAD1 is autopalmitoylated. Taken together, we have shown that TEADs have a 
conserved hydrophobic pocket occupied by a palmitate, revealing a new structural feature of 
these transcription factors. The lipid-binding pocket is highly conserved among other 
TEADs32. Therefore, palmitate-binding could be an important regulatory mechanism for all 
TEADs.
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The structural studies suggested that TEAD1 C359 (corresponding to TEAD2 C380) 
palmitoylation is stable and can be crystalized. However, we cannot rule out that C327 
(corresponding to TEAD2 C348) is partially or transiently palmitoylated in cells as shown in 
our in cell labeling experiments. We purified recombinant TEAD2 C380S and C348/380S 
(2CS) mutant. Consistent with the mutagenesis studies in Fig.2a and 2b, TEAD2 C380S 
mutant can still be autopalmitoylated in vitro, but TEAD2 2CS mutant cannot 
(Supplementary Fig. 5). These results suggest that both C348 and C380 are involved 
palmitoylation, and C380 palmitoylation is more stable.
It has been noted before that TEADs are structurally related to phosphodiesterase δ (PDEδ, 
PDB code 1KSHB and 3T5I)27,31,32,34, with two β-sheets packing against each other to form 
a β-sandwich motif. Interestingly, PDEδ has a similar hydrophobic pocket inside the β-
sandwich motif, which binds to the farnesyl chain of GTPases35,36 (Supplementary Fig. 6). 
It is possible that such structural motif represents a common lipid-binding site, and other 
proteins with similar motif might also bind to lipid ligands. Interestingly, small molecule 
inhibitors of PDEδ can indeed bind to this pocket, and inhibit the association of PDEδ and 
farnesylated Ras proteins, leading to inhibition of Ras activities. Therefore, targeting such 
lipid-binding sites might lead to new small molecule inhibitors of important biological 
pathways.
Palmitoylation of TEAD regulates TEAD-YAP/TAZ association
Although all 4 TEAD proteins are palmitoylated, we focused on our functional studies using 
TEAD1, as it is one of the most abundant TEAD proteins ubiquitously expressed. As the 
palmitoylated cysteine (C359 of TEAD1) is located near the TEAD–YAP interface, we 
tested whether palmitoylation could allosterically regulate TEAD–YAP association. Indeed, 
we found that YAP could co-immunoprecipitate (co-IP) with WT TEAD1, but the 
association was significantly reduced with the palmitoylation-deficient mutants (C359S, 
C327/359S (2CS) or 3CS) (Fig. 4a). In addition, we tested TEAD–YAP/TAZ interaction 
using Gal4-TEAD1 or TEAD2 fusion protein, which can activate a Gal4-responsive 
luciferase reporter upon YAP or TAZ binding26,27,31. We found that Gal4-TEAD1/2 WT can 
activate the Gal4-repsonsive luciferase in the presence of YAP or TAZ, indicating of forming 
of active transcription complex. However, the palmitoylation-deficient mutants (C359S, 2CS 
and 3CS) have significantly reduced activities (Fig. 4b, Supplementary Fig. 7a–b), with 
TEAD 2CS and 3CS mutant lost most of the activities. Furthermore, a FRET-based binding 
assay (Alpha Screen) between TEAD1 and YAP also confirmed that TEAD mutant (C359S) 
had weaker association with YAP, and the palmitoylation-deficient mutants (2CS and 3CS) 
lost binding to YAP (Fig. 4c). Taken together, our results showed that palmitoylation of 
TEAD plays important roles in regulating its binding to transcription co-activators. We next 
examined the functional roles of TEAD palmitoylation. We observed that TEAD1 C359S 
mutant is partially defective in YAP-induced transcriptional activities. Consistently, TEAD1 
2CS or 3CS mutant lost the activities in TEAD-binding element reporter (8×GTIIC-Luc) 
assays (Fig. 4d)37, suggesting that blocking TEAD palmitoylation impairs its transcriptional 
activity.
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In addition, both TEAD1 WT and 3CS mutant localized similarly in the nucleus 
(Supplementary Fig. 7c–e), suggesting that palmitoylation does not alter TEAD1 
localization. These findings were consistent with our observations that palmitate binds to a 
deep pocket inside of TEAD. Unlike other palmitoylated proteins, palmitate might not serve 
as a membrane anchor for TEADs. Therefore, our results have uncovered new functions of 
protein palmitoylation in regulating transcription factor complexes.
Moreover, we found that TEAD2 2CS/3CS mutants were properly folded. It has been 
reported that TEADs can bind to Vgll4, a tumor suppressor that competes with YAP for 
TEAD binding, and consequently inhibits YAP oncogenic activity8. In the co-IP assay, we 
found that TEAD1 WT and the palmitoylation-deficient mutants (C359S, 2CS or 3CS 
mutants) are able to bind to Vgll4 (Fig. 4e). Consistently, in the FRET-based (Alpha Screen) 
binding assay, TEAD1 WT, C359S, 2CS and 3CS mutants all bind to Vgll4 similarly (Fig. 
4f). Taken together, we showed that palmitoylation is required for TEAD1–YAP binding, but 
is dispensable for TEAD1–Vgll4 binding. In addition, as TEAD1 C359S, 2CS and 3CS 
mutants are still capable of binding to Vgll4, the loss of YAP binding are not due to 
misfolding.
In crystal structures, palmitate does not directly interact with YAP. Therefore, palmitate 
allosterically regulates YAP binding. It has been shown that YAP binds to TEAD through 
three interfaces31,32. Mutations of TEAD residues at interface III greatly inhibited YAP, not 
Vgll4 binding, suggesting interface III is more critical for YAP binding31,32. We hypothesize 
that palmitoylation allosterically changes the conformation of TEAD at or near interface III, 
thus regulating YAP binding, but not Vgll4 binding. Our results and a recent report have 
suggested that binding of palmitate rigidifies the structure of TEAD30. We speculate that it 
might affect the local side chain dynamics around the binding interface III, which was 
required for YAP binding. Further structural and protein side-chain dynamic studies using 
NMR spectrometry will provide more details about how palmitate allosterically regulates 
TEAD protein dynamics. Interestingly, fatty acylation has been shown before to 
allosterically regulate protein functions. For example, N-terminal myristoyl modification of 
c-Abl binds to the kinase domain and induces conformational changes of the protein, 
resulted in autoinhibition of c-Abl kinase activity38,39.
Palmitoylation regulates TEAD physiological functions
We next examined the physiological roles of TEAD palmitoylation. It has been shown that 
TAZ promotes terminal differentiation and myotube fusion of skeletal muscle cells through 
TEAD1 and TEAD440–42. A TEAD4 mutant (TEAD4-DBD), which lacks YAP/TAZ 
binding domain, functioned as a dominant negative mutant and inhibited C2C12 myoblast 
differentiation and myotube fusion40. Therefore, TEAD–TAZ association is critical for 
myogenesis. As TEAD palmitoylation is required for TAZ binding, we speculate that loss of 
TEAD palmitoylation might impair myogenesis. To test this hypothesis, we stably 
transfected C2C12 myoblast cells with TEAD1 WT or 3CS mutant, and then induced them 
to differentiate. We evaluated muscle differentiation by immunostaining of myosin heavy 
chain (MHC). TEAD1 3CS strongly inhibited muscle differentiation and myotube fusion, 
compared to vector control and TEAD1 WT (Fig. 5a, Supplementary Fig. 8a). C2C12 cells 
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expressing TEAD1 3CS showed significantly lower differentiation index and fusion index 
(Fig. 5b–c). In addition, we observed that expression of TEAD1 3CS mutant blocked muscle 
differentiation gene (Mef2C, MyoG1, Myh4), as well as TEAD-specific target genes (CTGF 
and Cyr61) expression by qRT-PCR (Fig. 5d–e, Supplementary Fig. 8b–c). Taken together, 
our results suggested that palmitoylation is required for TEADs’ normal physiological 
functions in muscle differentiation in vitro.
To further corroborate the functional significance of TEAD palmitoylation, we compared the 
ability of wild type Drosophila Scalloped (Sd) or palmitoylation-deficient (2CS) mutant 
(both constructs targeted to the same genetic locus to avoid positional effect of transgene 
insertion) to cooperate with Yorkie (Yki) in promoting tissue overgrowth using a sensitive in 
vivo assay. Differential splicing of Yki results in two isoforms containing two WW domains 
(Yki-PG and Yki-PF, Flybase) or a single WW domain (Yki-PD, Flybase). Unlike Yki-PG 
whose overexpression resulted in eye overgrowth5, overexpression of Yki-PD alone resulted 
in only slightly bigger eye sizes, but such changes are not statistically significant (Fig. 6a–d). 
Nevertheless, co-expression of Yki-PD and Sd (WT) caused a significant enlargement of eye 
size (Fig. 6e), providing a very sensitive assay for Sd–Yki complex in driving tissue 
overgrowth. Interestingly, this overgrowth phenotype was significantly compromised when 
Yki-PD was co-expressed with the palmitoylation-deficient Sd (2CS) mutant (Fig. 6f). We 
have quantified the eye sizes in all the flies, and have performed statistical analysis (Fig. 6g). 
In addition, the top views of the flies (Supplementary Fig. 9a–f) showed the size of eyes 
from a different angle. Interestingly, both Sd WT and 2CS mutant have statistically 
significant reduction of eye growth compared to WT flies (Fig. 6b, c, and g), which is 
consistent with the default repressor functions of Sd43. The difference between Sd WT and 
2CS mutant is not statistically significant. Therefore, it is likely that loss of palmitoylation in 
Sd (2CS) does not affect its default repressor functions. This result is consistent with our 
findings in human cells, where TEAD1 (2CS) can still bind to Vgll4. To better evaluate the 
effects on target genes, we performed qRT-PCR analysis of Diap1 and Expanded in fly S2 
cells with the expression of the 2CS mutant or WT Scalloped. Consistently, expression of 
Yki and WT Scalloped induced the expression of both genes, while expression of Yki and 
Scalloped 2CS mutant significantly compromised the target gene expression in fly cells 
(Supplementary Fig. 9g–h). Taken together, our results suggest that palmitoylation is 
required for the physiological function of the TEAD transcription factors.
DISCUSSION
In summary, using chemical approaches, we have revealed that TEADs are specifically 
autopalmitoylated at evolutionarily conserved cysteine residues. Autopalmitoylation has 
been considered as a non-specific reaction of surface cysteine residues with high 
concentration of palmitoyl-CoA. However, our studies, together with the studies of yeast 
Bet3 protein, have shown that autopalmitoylation could happen under physiological 
conditions, with specific cysteine residues being modified. As there are only 23 DHHC-
PATs, it is unlikely that they are responsible for all the palmitoylation activities in cells 
(more than 1000 protein substrates are S-palmitoylated). Therefore, it is possible that many 
S-palmitoylated proteins are modified through PAT-independent processes, and 
autopalmitoylation could be an important regulation for protein functions. Our studies have 
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demonstrated for the first time to systematically identify autopalmitoylated proteins using 
chemical tools.
Palmitoylation has been commonly linked to membrane attachment and protein 
trafficking10,15. Our results have shown that palmitate binds to a hydrophobic pocket in the 
core of the protein, and does not regulate protein membrane binding. It has been noted that 
in the crystal structures of yeast Bet3 protein, the covalently attached palmitate also binds 
into a hydrophobic pocket in the protein44. Palmitoylation of Bet3 stabilizes the protein and 
is involved in regulating Bet3 degradation and co-factor binding18. Therefore, in addition to 
acting as a membrane-binding moiety, palmitoylation of proteins indeed has other important 
functions. Further studies of additional autopalmitoylated proteins will likely reveal new 
functions of protein palmitoylation.
We have observed that TEAD1 C359 is the major and stable site of modification, which is 
located at the opening of the lipid-binding pocket. We could not purify and crystalize 
palmitate-free TEAD2, and it is likely that binding of palmitate stabilized the conformation 
of TEAD, allowing the protein to be crystalized. Nevertheless, TEAD proteins might exist as 
palmitoylated and non-palmitoylated species in cells. We have also observed that TEAD2 
C380S remains autopalmitoylated, but not the C348/380S mutant, consistent with the 
observation that TEAD 2CS/3CS mutant has more significant loss of activity than C380S. 
Although we did not observe the lipid modification of C348 in the crystal structures, which 
are only snapshots of the most stable conformations of the protein, both C348 and C380 
should be involved in palmitoylation. It is possible that C348-palmitoylated TEAD2 has a 
different conformation, allowing palmitate to bind to the conserved deep pocket. In addition, 
another hydrophobic pocket near the surface is close to C348 in TEAD2 structure, which 
could accommodate the binding of hydrophobic ligands, such as bromofenamic acid 
(BFA)45. Further studies would be needed to reveal the detailed structures of C348-
palmitoylated TEAD2.
As the levels of TEAD autopalmitoylation are highly relevant to the palmitoyl-CoA 
concentrations in cells. The cellular palmitoyl-CoA pool might be an upstream regulator of 
TEAD’s activities and Hippo pathway. Fatty acid synthase (FASN) is the key enzyme that 
synthesizes palmitoyl-CoA from acetyl-CoA and malonyl-CoA46. FASN has been proposed 
as a potential oncogene, which is upregulated in breast cancers and its expression is 
associated with poor prognosis46. High level of FASN might lead to high intracellular 
palmitoyl-CoA, thus promoting TEAD–YAP mediated oncogenic processes. Further studies 
would be needed to test whether TEAD–YAP activities are responsible for tumorigenesis in 
FASN-overexpressed cancer cells. Currently, we don’t have evidence that TEAD proteins 
can be palmitoylated and depalmitoylated in a dynamic fashion. Two potential 
depalmitoylating enzyme families, acylprotein thioesterases (APT1/2) and protein 
palmitoylthioesterases (PPT1/2) have been reported47,48. It would be interesting to 
investigate whether these enzymes contribute to TEAD depalmitoylation.
It remains challenging to develop potent and selective small molecule inhibitors to disrupt 
TEAD-YAP interaction, as the interaction interface is shallow and spans over a large area on 
the surface. Our results showed that the palmitate-binding pocket of TEADs is deep and 
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hydrophobic, ideal for inhibitor binding. Indeed, a recent study has shown that this pocket is 
accessible by small molecules, although their potency and selectivity are not optimal45. 
Taken together, targeting autopalmitoylation of TEADs by small molecules could be a new 
strategy for drug discovery.
ONLINE METHODS
Labeling, Click reactions and streptavidin pull-down
HEK293A or MCF10A cells were labeled with DMSO or probe 1, 2 or 3 overnight. Cells 
were lysed in lysis buffer (50 mM TEA-HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100, 0.2% 
SDS, cOmplete EDTA-free protease inhibitors) followed by Click reaction with biotin-
azide22. Proteins were precipitated with 9 volumes of 100% methanol for 2 h or overnight at 
−20°C. Proteins were recovered by centrifugation at 14,000 × g for 10 min and the 
precipitants were suspended in suspension buffer (50 mM Tris-HCl, pH 7.7, 150 mM NaCl, 
10 mM EDTA, 1% SDS, 0.5% NP-40). Labeled cellular proteins were enriched using 
streptavidin agarose (Life technologies) at room temperature with rotation overnight. 
Protein-bound streptavidin agarose beads were washed three times with suspension buffer 
without NP-40 and bound proteins were eluted with elution buffer (30 mM D-Biotin, 2% 
SDS, 6M Urea). Samples were processed with SDS-PAGE sample buffer and proteins were 
resolved by SDS-PAGE. TEAD 1 – 4 in these samples were detected using TEAD-specific 
antibodies and streptavidin HRP. Blots were probes with anti-TEAD1 (#8526, 1:1000, Cell 
Signaling), anti-TEAD2 (#8870, 1:1000, Cell Signaling), anti-TEAD3 (#13224, 1:1000, Cell 
Signaling), anti-TEAD4 (ab58310, 1:1000, Abcam) and Streptavidin HRP (1:5000, Life 
technologies).
Cell culture
HEK293A, Phoenix, MCF10A and C2C12 cell lines (obtained from ATCC, Manassas, VA) 
were grown at 37°C with 5% CO2. HEK293A, Phoenix, and C2C12 cell lines were cultured 
in Dulbecco’s modified Eagles media (DMEM) (Life technologies) supplemented with 10% 
fetal bovine serum (FBS) (Thermo/Hyclone, Waltham, MA) and 50µg/mL penicillin/
streptomycin. MCF10A cells were cultured in DMEM/F12 (Life technologies) 
supplemented with 5% horse serum, 20 ng/mL EGF, 0.5 µg/mL hydrocortisone, 100 ng/mL 
cholera toxin, 10 µg/mL insulin and 50 µg/mL penicillin/streptomycin. None of cell lines 
used in this paper listed in the database of commonly misidentified cell lines maintained by 
ICLAC. All cell lines are free of mycoplasma contamination.
Transfection and transduction
Plasmids were transfected with jetPRIME (Polyplus transfection) or XtremeGene HP 
(Roche) according to the manufacturer’s instructions.
For retrovirus production, Phoenix cells were transfected with VSV-G and empty pBabe 
hygro or pBabe hygro containing TEAD1 wild type or 3CS mutant cDNA. Supernatants 
were collected by centrifugation and filtered through a 0.45 µm syringe filter (Corning) 48 h 
post-transfection. Cells were infected with 2 mL viral supernatant in the presence of 10 
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µg/mL polybrene (Millipore). Cells were incubated for 24 – 48 h before splitting into 
selection medium.
Site-directed mutagenesis
Mutagenesis was performed using QuikChange II Site-Directed Mutagenesis kit (Agilent) 
following manufacturer’s instructions.
Co-immunoprecipitation
HEK-293A cells were transfected with the indicated constructs. After 48 h, cells were lysed 
with lysis buffer (50 mM Tris-HCl, pH 7.3, 150 mM NaCl, 0.5 mM EDTA, 1% Triton 
X-100, PhosSTOP phosphatase inhibitor cocktail, cOmplete EDTA-free protease inhibitors 
cocktail). Flag-YAP or Myc-TEAD1 was immunoprecipitated with anti-FLAG M2 magnetic 
beads (Sigma Aldrich) or anti-c-Myc antibody (M4439, Sigma Aldrich), respectively, 
overnight with rotation at 4°C. TEAD1 was captured using Protein A/G magnetic resins 
(Life technologies). Protein-bound resins were washed three times with lysis buffer and 
processed with SDS-PAGE sample buffer. Blots were probed with anti-c-Myc (Sigma 
Aldrich), anti-HA (Sigma Aldrich), anti-FLAG M2 (F1804, Sigma Aldrich).
FRET-based Alpha screen binding assay
Myc-TEAD1 and Flag-YAP or Flag-VGLL4 were transfected into HEK293A cells and 24 – 
48 h post-transfection, cells were lysed with lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, PhosSTOP phosphatase inhibitor 
cocktail, cOmplete EDTA-free protease inhibitor). Anti-c-myc acceptor beads (Perkin 
Elmer) were added to each well and incubated for 2 h prior to addition of anti-FLAG donor 
beads (Perkin Elmer). Samples were incubated overnight in darkness and Alpha signals were 
recorded using Perkin Elmer EnVision plate reader.
Luciferase assay
Gal-UAS-Luc, YAP, Gal4-TEAD1, Gal4-DBD or Myc-TEAD1 and Renilla luciferase 
control constructs were transfected into 293T cells and 48 h post-transfection, cells were 
processed using the Dual-Glo luciferase assay system (Promega) following manufacturer’s 
instructions. Luminescence of Firefly and Renilla luciferase activities were quantified using 
Perkin Elmer EnVision plate reader.
Ni-NTA pull-down and acyl-biotin exchange
Recombinant His6TEAD2 was incubated with Ni-NTA resin (Life technologies) in PBS for 
1 h at 4°C. Protein-bound resins were washed and then incubated with 50 µM alkyne 
palmitoyl-CoA for 2 h at 25°C. Resins were split into two equivalent reactions, washed with 
PBS and treated with 50 mM NEM (Thermo Scientific) overnight at 4°C. Samples were 
incubated with or without 0.5 M hydroxylamine (Sigma Aldrich) for 1 h at room 
temperature and then incubated with 1 µM Biotin-BMCC (Pierce Biotechnology, Inc.) for 1 
h at room temperature. Samples were washed and processed with SDS-sample buffer. 
Proteins were resolved by SDS-PAGE and visualized by immunoblotting with streptavidin 
HRP, anti-His antibody (SAB1306085, Sigma Aldrich) or Coomassie blue staining.
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C2C12 cells differentiation
C2C12 cells were transduced using retrovirus containing vector control (pBabe hygro), wild 
type or 3CS TEAD1. Stable expression was selected initially using 600 µg/mL Hygromycin 
B (Life technologies) and then decreased to 300 µg/mL for 2 weeks. To induce 
differentiation, the culture condition was replaced by differentiation medium (DMEM + 2% 
horse serum + 50 µg/mL penicillin/streptomycin) with medium change everyday.
Immunofluorescence
Cells were fixed with 4% paraformaldehyde and then permeabilized and blocked with 3% 
(w/v) BSA/PBS + 0.1% Triton X-100 at room temperature for 30 min. Cells were 
immunostained with anti-myosin (skeletal, fast) chain (M4276, 1:400, Sigma Aldrich), anti-
Yap (1:1000, Abgent) or anti-c-myc (1:500, Sigma Aldrich) antibody overnight at 4°C. Cells 
were washed three times with PBS + 0.1% Triton X-100 followed by incubation with 
Alexafluor 488 conjugated anti-mouse secondary antibody (1:500, Life technologies) and 
Hoechst 33258 (1:2500, Life technologies) at room temperature for 2 h. Cells were washed 
again and images were captured using Nikon Digital Sight microscope.
Drosophila Genetics
UAS-ykiPD construct was generated by cloning the yki single WW domain isoform (Yki-
PD) cDNA into the pUAST vector. UAS-sdWT and UAS-sd2CS constructs were generated by 
cloning wild-type scalloped (sd) or sd palmitoylation-deficient (2CS) mutant cDNA into the 
pUAST-attB vectors. UAS-ykiPD transgenic fly was created by conventional transposon-
mediated transformation. UAS-sdWT and UAS-sd2CS transgenic flies were created by 
phiC31-mediated site-specific transformation, using the attP2 site at 51C. GMR-Gal4 was 
used for overexpression analysis. All crosses were done at 25°C. The quantification of fly 
eyes were carried out by analyzing the eye area in the images49, and normalized to the 
control wild type flies. n=10 for each genotypes. The qRT-PCR analysis of Diap-1 and 
Expanded was carried out using primer sequences previously reported49.
Protein Purification and Crystallization
The cDNA encoding human TEAD2 (residues 217–447, TEAD2217–447) was cloned into a 
pET29 vector (EMD Biosciences) that included a C-terminal His6-tag. The construct was 
verified by DNA sequencing. The pET29-TEAD2217–447 plasmid was transformed into the 
E. coli strain BL21(DE3)-T1R cells (Sigma) for protein expression. His6-tagged 
TEAD2217–447 was purified with Ni2+-NTA agarose resin (Qiagen) and then purified by 
anion exchange chromatography with a resource-Q column followed by size exclusion 
chromatography with a Superdex 75 column (GE Healthcare). Purified TEAD2217–447 was 
concentrated to 4 mg/ml in a buffer containing 20 mM Tris (pH 8.0), 100 mM NaCl, 2 mM 
MgCl2, 1 mM TCEP and 5% glycerol.
Crystals of TEAD2217–447 were grown at 20°C using the hanging-drop vapor-diffusion 
method with a reservoir solution containing 0.1 M Hepes (pH 7.2) and 2.4 M sodium 
formate. The crystals were cryo-protected with reservoir solution supplemented with 25% 
glycerol and then flash-cooled in liquid nitrogen.
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In vitro Palmitoylation
Recombinant GST-TEAD2 or His6TEAD2 (500 ng) protein was incubated with the 
indicated concentrations of alkyne palmitoyl-CoA (Cayman Chemical) for 2 h or the 
indicated time in 50 mM MES, pH 6.4. The reaction was quenched with 1% SDS followed 
by Click reaction as described previously. Samples were analyzed by SDS-PAGE and 
streptavidin HRP. Bands intensity obtained from streptavidin blot were quantified using 
Image J (NIH) and the rate of palmitoylation in arbitrary unit was plotted against the 
concentration of palmitoyl-CoA. The data was fitted to the Michaelis-Menten equation using 
Prism v.6.0 (GraphPad). For mass spectrometry analysis, recombinant TEAD2 YBD (1 
mg/ml) was incubated with 1 eq. of palmitoyl-CoA for 30 min at room temperature in a 
buffer containing 50 mM MES, pH 6.4.
Data Collection and Structure Determination
Diffraction data were collected at beamline 19-ID (SBC-CAT) at the Advanced Photon 
Source (Argonne National Laboratory) at the wavelength of 0.9791 Å at 100 K and 
processed with HKL3000. Phases were obtained by molecular replacement with Phaser 
using the crystal structure of human TEAD2 (PDB code: 3L15) as the search model. 
Iterative model building and refinements were carried out with COOT and Phenix, 
respectively. MolProbity was used for structure validation to show that all models have good 
geometry. Data collection and structure refinement statistics are summarized in 
Supplementary Table 1. Ramachandran statistics (Favored/allowed/outlier (%)) are 
97.4/2.6/0.0. The crystal structure of palmitate-bound TEAD1–YAP was obtained by 
building two thioester-linked palmitate molecules into TEAD1–YAP (PDB code: 3KYS) 
with COOT using the electron density map calculated from 3KYS structure factor. The final 
model was refined with Phenix.
Statistical Analysis
No statistical method was used to predetermine sample size. The experiments were not 
randomized. For biochemical experiments we performed the experiments at least three 
independent times. Experiments for which we showed representative images were performed 
successfully at least 3 independent times. No samples or animal were excluded from the 
analysis. The investigators were not blinded to allocation during experiments and outcome 
assessment. All P values were determined using two-tailed t-tests and statistical significance 
was set at P = 0.05. The variance was similar between groups that we compared.
Database
PDB: 5HGU
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Chemical approaches reveal that TEA domain (TEAD) transcription factors are 
palmitoylated
(a) Structures of the chemical reporter of palmitoylation (1), and the activity-based chemical 
probes for palmitoyl acyltransferases (PATs) and autopalmitoylated proteins (2 and 3).
(b) 1 and 2 labeled myc-TEAD1 and myc-TEAD4 in HEK293A cells. The streptavidin blot 
showed the palmitoylation of TEADs.
(c) Endogenous human TEAD1– 4 are all palmitoylated. The palmitoylated proteome of 
HEK293A and MCF10A cells was labeled by 1, and enriched by streptavidin beads. Western 
blots of TEAD1– 4 were carried out in the pull-down samples using anti-TEAD1, 2, 3, 4 
antibodies. See Supplementary Fig. 10 for the full image of the blots.
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(d) TEAD1 is S-palmitoylated and hydroxylamine treatment dramatically decreased its 
palmitoylation levels. See Supplementary Fig. 10 for the full image of the blots.
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Figure 2. TEAD is autopalmitoylated at evolutionarily conserved cysteine residues under 
physiological palmitoyl-CoA concentrations
(a) Mutation of the conserved cysteine residues (C53, C327 and C359) to serine residues 
individually or in combination (b) blocked palmitoylation of TEAD1. See Supplementary 
Figure 11 for the full image of the blots.
(c) Recombinant TEAD2 protein (YAP binding domain, YBD) is autopalmitoylated in vitro 
in the presence of alkyne palmitoyl-CoA. See Supplementary Fig. 11 for the full image of 
the blots.
(d) Mass spectrometry analysis of recombinant TEAD2 YBD reveals palmitoylation of 
TEAD2.
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(e) Acyl-biotin exchange (ABE) assay confirmed autopalmitoylation of recombinant TEAD2 
YBD. See Supplementary Fig. 11 for the full image of the blots.
(f) The Km value of palmitoyl-CoA in TEAD2 autopalmitoylation was estimated by plotting 
the reaction rate against the substrate concentration.
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Figure 3. Structures of palmitate-bound human TEAD2 YBD and TEAD1–YAP complex
The Fo – Fc omit electron density map for TEAD2 (a) and TEAD1–YAP (c) at the contour 
level of 2.5σ. Palmitate (PLM) is shown as yellow sticks, and surrounding residues are 
shown as cyan sticks. Palmitate is covalently linked to C359 of TEAD1 (c). Ribbon diagram 
(left) and electrostatic surface (right) of PLM-bound TEAD2 YBD (PDB code: 5HGU) (b) 
and TEAD1–YAP complex (d) are shown. TEADs are colored in cyan and YAP is colored in 
pink. Two conserved cysteine residues are shown. The surface opening in free TEAD2 and 
the corresponding position in TEAD1–YAP are indicated by red arrow. All structural figures 
were generated with PyMOL (https://www.pymol.org).
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Figure 4. Palmitoylation of TEAD is required for its association with YAP/TAZ
(a) Palmitoylation-deficient mutants of TEAD1 (C359S, C327/359S (2CS), and 3CS) have 
decreased association with YAP in co-immunoprecipitation (co-IP) experiments. See 
Supplementary Fig. 12 for the full image of the blots.
(b) YAP binds to and significantly activates Gal4-TEAD1 wild type (WT) in Gal4-
responsive luciferase assay. The palmitoylation-deficient Gal4-TEAD1 mutants (C359S, 
2CS and 3CS) significantly inhibits Gal4-responsive luciferase reporter. (Data are 
represented as mean ± SEM, n=3. P values were determined using two-tailed t-tests. ****, 
p<0.0001, **, p<0.005).
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(c) FRET-based binding assay (Alpha Screen) showed that TEAD1 palmitoylation-deficient 
mutants (C359S, 2CS and 3CS) have decreased binding to YAP, comparing to TEAD1 WT. 
(Data are represented as mean ± SEM, n=3. P values were determined using two-tailed t-
tests. ***, p<0.0005).
(d) Palmitoylation-deficient mutants of TEAD1 (C359S, 2CS, and 3CS) significantly 
decreased TEAD transcription activity shown in a TEAD-binding element driven luciferase 
reporter assay (8XGTIIC-luciferase). (Data are represented as mean ± SEM, n=3. P values 
were determined using two-tailed t-tests. *, p<0.05; **, p<0.005).
(e) Palmitoylation-deficient mutants of TEAD1 (C359S, 2CS, and 3CS) retain the binding to 
Vgll4 tumor suppressor in co-immunoprecipitation (co-IP) experiments. See Supplementary 
Fig. 12 for the full image of the blots.
(f) FRET-based binding assay (Alpha Screen) showed that TEAD1 palmitoylation-deficient 
mutants (C359S, 2CS and 3CS) and TEAD1 WT bind to Vgll4 similarly. (Data are 
represented as mean ± SEM, n=3. P values were determined using two-tailed t-tests. N.S., 
not significant)
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Figure 5. Palmitoylation regulates TEAD functions in muscle cell differentiation in vitro
(a) Representative images of myosin heavy chain (MHC, green) immunostaining of C2C12 
cells. C2C12 cells stably expressing vector control (pBabe Hygro), TEAD1 WT or TEAD1 
3CS mutant, were induced to differentiate for 3 days. Cell nuclei were stained with DAPI 
(blue). Scale bar: 100µm.
(b–c) TEAD1 3CS mutant significantly inhibited myogenic differentiation and myotube 
fusion. Differentiation and fusion indices were calculated by averaging the data obtained 
from five different fields. (Data are represented as mean ± SEM, n=5. P values were 
determined using two-tailed t-tests. **, p<0.005).
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(d–f) TEAD 3CS mutant blocked the expression of myogenic markers Mef2C, and TEAD 
target genes (CTGF and Cyr61) in C2C12 cell. RNA samples of C2C12 stably expressed 
vector control, wild type and 3CS mutant of TEAD1 were collected and cDNA of each were 
synthesized. mRNA levels of each gene were determined by qRT-PCR using SYBR Green 
and normalized to GAPDH. (Data are represented as mean ± SEM, n=3. P values were 
determined using two-tailed t-tests. **, p<0.01)
Chan et al. Page 25
Nat Chem Biol. Author manuscript; available in PMC 2016 August 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. Palmitoylation is required for the functions of Drosophila TEAD protein Scalloped (Sd) 
in vivo
Images of compound eyes from the following genotypes: (a) GMR-gal4/+, (b) GMR-gal4/
UAS-sdWT, (c) GMR-gal4/UAS-sd2CS, (d) GMR-gal4, UAS-ykiPD, (e) GMR-gal4, UAS-
ykiPD/UAS-sdWT, (f) GMR-gal4, UAS-ykiPD/UAS-sd2CS. Scale bar: 150µm.
Note the overgrowth phenotype (enlarged eyes with rough surface) caused by co-expression 
of Yki-PD and Sd (WT) (e) is compromised when Yki-PD is co-expressed with the 
palmitoylation-deficient Sd (2CS) mutant (f). The images were taken with the same 
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magnification. The size of the eye in wild type control flies is marked in blue dashed line, 
and the same area is shown in all images to facilitate comparison across all genotypes. (g) 
Relative sizes of the fly eyes are quantified in indicated genotypes. Sd WT and Sd 2CS flies 
are compared to the wild type, with statistically smaller eyes. (Data are represented as mean 
± SEM, n=10 for each genotype. P values were determined using two-tailed t-tests. *, 
p<0.05; ***, p<0.001)
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